An Apoferritin–Hemagglutinin Conjugate Vaccine with Encapsulated Nucleoprotein Antigen Peptide from Influenza Virus Confers Enhanced Cross Protection

Jiangxue Wei,Zhengjun Li,Yanli Yang,Guanghui Ma,Zhiguo Su,Songping Zhang
DOI: https://doi.org/10.1021/acs.bioconjchem.0c00308
IF: 4.7
2020-07-17
Bioconjugate Chemistry
Abstract:Naturally occurring self-assembling ferritin nanoparticles have become widely appreciated for vaccine design. In this study, an apoferritin (AFt) nanocage was used as a carrier to construct a biomimetic influenza vaccine by encapsulating a conserved internal nucleoprotein (NP) antigen peptide inside the nanocage, followed by chemically conjugating the surface antigen hemagglutinin (HA) protein on the outer surface of the AFt. Benefiting from the excellent thermal stability and thermallyassociated structural flexibility of the AFt nanocages, a novel temperature shift based encapsulation process was proposed and proved efficient for encapsulation of the NP peptides. On average, about 18 NPs were encapsulated and 1.6 HA antigens were conjugated in each of the HA-AFt+NP dual-antigen influenza vaccines. Upon immunization in mice, the HA-AFt+NP vaccine elicited both HA and NP-specific antibodies, and conferred complete protection against a lethal infection of both homologous PR8 H1N1 and heterologous A/FM/1/47 (FM1, H1N1) strains, while the HA-AFt conjugate vaccine without encapsulated NP antigen only conferred 60% protection against the FM1 H1N1 viral challenge. The potential cross-protective effect of the HA-AFt+NP vaccine was further demonstrated by significant specific hemagglutination inhibition (HAI) titers in serum of the immunized mice against heterologous A/Hong Kong/4801/2014 (H3N2) viral strain, which was about 3-fold of that induced by HA antigen and 2-fold of the HA-AFt conjugate vaccine. This biomimetic HA-AFt+NP conjugate vaccine, therefore, may represent a new strategy for developing a potential universal influenza vaccine without the need of any adjuvant, and further broaden the application of AFt nanocages in the areas of vaccine development and delivery system.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.bioconjchem.0c00308?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.bioconjchem.0c00308</a>.Additional details on experimental condition and operation of HPSEC, CD, DLS, MALDI-TOF MS and RP-HPLC analyses. The MALDI-TOF data of AFt+NP after acidolysis (Figure S1). The AFt-specific antibody data of AFt and HA-AFt groups (Figure S2). (<a class="ext-link" href="/doi/suppl/10.1021/acs.bioconjchem.0c00308/suppl_file/bc0c00308_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.
chemistry, multidisciplinary,biochemistry & molecular biology, organic,biochemical research methods
What problem does this paper attempt to address?